Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Entera Bio Ltd. (ENTX)

Entera Bio Names Riccardo Paolo Camisasca Chief Medical Officer Effective Immediately

Neutral Impact 3 of 5 leadership Written later

Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer effective August 18, 2026. The company said the hire comes ahead of the planned Phase 3 initiation of its EB613 oral osteoporosis candidate, which it describes as its most advanced product candidate.

Key points

  • Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer, effective immediately on August 18, 2026
  • Dr. Camisasca has more than 30 years of experience, most recently as Global Head of Research & Development at Sumitomo Pharma Switzerland
  • Company plans to initiate a Phase 3 program for EB613, its oral PTH(1-34) tablet candidate for osteoporosis

The filing

CompanyEntera Bio Ltd. (ENTX)
Form8-K, current report
Filed with the SECAug 18, 2026, 8:00 AM ET
Accession number0001178913-26-004178

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.